Open AccessCommunity-acquired Methicillin- resistant Staphylococcus Aureus, a New Player in Sports Medicine
Author(s) -
Doanh Lu,
Paul Holtom
Publication year - 2005
Publication title -
current sports medicine reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.424
H-Index - 51
eISSN - 1537-8918
pISSN - 1537-890X
DOI - 10.1097/01.csmr.0000306220.17928.7c
Subject(s) - linezolid , medicine , clindamycin , daptomycin , methicillin resistant staphylococcus aureus , dalfopristin , staphylococcus aureus , doxycycline , quinupristin , vancomycin , trimethoprim , intensive care medicine , antibiotics , microbiology and biotechnology , biology , bacteria , genetics
Community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) has emerged as a major pathogen, with distinct clinical characteristics and target populations. It has a striking ability to infect the young and the healthy. Persons in crowded conditions are at risk, including athletes, military personnel, jail inmates, and children in daycare. Most CA-MRSA infections are composed of simple and complicated skin and soft tissue infections; invasive disease occurs in 6% to 10% of cases. CA-MRSA infections can be treated with trimethoprim-sulfamethoxazole, doxycycline, or clindamycin. For severe infections, vancomycin, daptomycin, quinupristin/dalfopristin, or linezolid can be used. Infection control should be an integral part of any CA-MRSA treatment program.